PMID: 18727403Aug 30, 2008Paper

Cell therapy for myocardial infarction

Tsitologiia
P V KrugliakovD G Polyntsev

Abstract

The review discusses cell therapy; one of the most promising approaches to myocardial infarction treatment. The possibility to use cell material of various origins is analyzed. The review sums up data on the application of fetal and neonatal cardiomyocytes, myoblasts, bone marrow mononuclear fraction, hematopoietic and mesenchymal stem cells (MSX) as cell therapy agents. The conclusion is made that MSC are promising cell material for myocardial infarction therapy. MSC are able to migrate to the injured area, differentiate into myocardial lineage. They produce a wide range of factors that stimulate angiogenesis and increase viability of cells, including cardiomyocytes.

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Related Papers

Rossiĭskii fiziologicheskiĭ zhurnal imeni I.M. Sechenova
T V Lelekova
Vnitr̆ní lékar̆ství
Y Pospísilová
Current Stem Cell Research & Therapy
Huan LiuLiling Tang
Expert Opinion on Biological Therapy
Tetsuhiro TsurumaKoichi Hirata
© 2022 Meta ULC. All rights reserved